COMBINED TREATMENT WITH BORTEZOMIB & DACARBAZINE

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。假说是，硼替佐米和达卡巴肼的联合治疗将提高黑色素瘤和软组织肉瘤的治疗效果。这些试验的具体目的是：(1)确定达卡巴肼和硼替佐米联合用药的推荐剂量；(2)确定联合用药的最大耐受量；(3)从有效率(S)、有效时间、进展时间和治疗时间(衡量抗肿瘤活性和治疗耐受性)的角度观察抗肿瘤活性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The hypotheses is that combined treatment with bortezomib and dacarbazine will result in enhanced therapeutic efficacy in melanoma and soft tissue sarcoma. The specific Aims are to : (1) Determine the recommended doses for the combination dacarbazine and bortezomib administered weekly; (2) Determine the maximum tolerated dose combination; and (3) Observe anti-tumor activity in terms of response rate(s), duration of response, time to progression, and time on treatment (a measure of both antitumor activity and treatment tolerance).